Eam Investors, LLC Denali Therapeutics Inc. Transaction History

Eam Investors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$53.8 - $81.53 $1.41 Million - $2.14 Million	-26,214 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$36.89 - $93.56 $552,353 - $1.4 Million	-14,973 Reduced 36.35%	26,214 $2.2 Million
Q3 2020 Nov 13, 2020	BUY	$23.13 - $38.84 $952,655 - $1.6 Million	41,187 New	41,187 $1.48 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.98B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.